Sodium-Glucose Co-Transporter 2 Inhibitors Should be the Standard [P1] of Care for Treatment of Most Patients with Heart Failure and Reduced Ejection Fraction Irrespective of Presence of Diabetes

Javad Javaheri*
Department of Nutrition and Metabolism, Arak University of Medical Sciences, 48412, Arak, Markazi, Iran
*Corresponding author: Javad Javaheri, Department of Nutrition and Metabolism, Arak University of Medical Sciences, 48412, Arak, Markazi, Iran
Received: January 20, 2020; Accepted: February 22, 2020; Published: February 29, 2020

Introduction

SGLT2 inhibitors are medications approved to treat type 2 diabetes. They decrease hyperglycemia independently of insulin by lowering the renal threshold for glucose and therefore increasing urinary excretion of glucose [1]. Recent large CV trials have consistently shown that these agents decrease HFH by 27-35% compared with placebo [2-4]. HFH is defined as HF syndrome with Left Ventricular Ejection Fraction (LVEF) ≤ 40% [5]. A large randomized trial, called the DAPA-HF Trial, published in late 2019 demonstrated that dapagliflozin significantly decreased HFH and mortality in patients with HFpEF [6]. The results of previous trials were not reflected on American practice guidelines because they were published after the release of Practice guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) [7]. The Heart Failure Association of the European Society of Cardiology (ESC) Consensus published in August 2019 reports that there is sufficient evidence to consider that the ability of SGLT2 inhibitors to prevent HF is a class effect. Yet, there is insufficient evidence to extend this observation to reductions in either CV or all-cause mortality or to patients without diabetes [8]. However, the latter Consensus was published after the release of the DAPA-HF Trial [6]. The author expects that the newer American and International guidelines will recommend SGLT2 inhibitors for standard management of most patients with HFpEF irrespective of existence of diabetes. This expectation is based on data showing that use of SGLT2 inhibitors results in first, prevention of HFH in patients with type 2 diabetes in both randomized and real-world studies, second: by effective treatment of actual HFpEF in patients with and without diabetes. Dapagliflozin did not cause major hypoglycemia in non-diabetic patients with heart failure. However, patients with advanced HFpEF with New York Heart Association (NYHA) class IV were not included.

Large randomized cardiovascular trials of SGLT2 inhibitors

Upon request of the Federal Drug Administration (FDA), pharmaceutical companies are required to design large clinical trials to prove CV safety of their products. Thus, 3 large randomized double-blind trials were published to examine CV safety of the 3 SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin (Table 1) [2-4]. The primary outcome in these trials was a composite of Major Adverse CV Outcome (MACE) defined as CV death, non-
**HFH=Heart Failure Hospitalization**

**CVD=Cardiovascular Disease**

| Table 1: Hospitalization due to heart failure in major randomized cardiovascular trials of SGLT2 inhibitors in patients with type 2 diabetes. |
|---|---|---|---|
| Trial | EMPA-REG [2] | CANAVA [3] | DECLARE [4] |
| SGLT-2 inhibitor | Empaglifoxin | Canagliflozin | Dapagliflozin |
| Patients | n=7020, mean age 63, 28% women | N=10142, mean age 63, 35.8% women | N=17160, mean age 64, 37.5% women |
| Patients with "CVD at baseline | 100% | 65% | 40% |
| Patients with heart failure at baseline | 10.10% | 14.40% | 10.00% |
| Follow-up | Median treatment 2.6 y, median observation 3.1 y | Mean 188 wks, median 126 wk | Median 4.2 y |
| Relative risk reduction in **HFH** (Hazard ratio, 95% CI) | 0.65 (0.5-0.85), P=0.002 | 0.87 (0.52-0.87), P value not reported | 0.75 (0.61-0.95), P value not reported |

As compared with initiation of sitagliptin over a mean follow-up of 5.3 months, hazard ration 0.50 (95% CI 0.21-0.91) [12]. Subgroup analysis by presence of baseline CV disease, history of heart failure, and gender yielded consistent results [12].

**SGLT2 inhibitors as treatment for heart failure in patients with and without diabetes**

Two studies were recently published to evaluate SGLT2 inhibitors as treatment for patients with HF irrespective of presence of diabetes. The first was a small short-term randomized trial using empagliflozin 10 mg/d in patients with HFREF (mean LVEF 26 ±6 %) [13]. After 12 weeks, significantly greater proportions of patients treated with empagliflozin experienced improvements in HF symptoms, functional status and quality of life as compared with placebo [13]. Results were the same whether patients had type 2 diabetes (166 of 263, 62%) or no diabetes (97 of 263, 38 %) [13].

The second study is a landmark randomized trial, the DAPA-HF trial, that examined the effect of dapagliflozin in 4,744 patients with HFREF with LVEF of 40% or less (Table 2) [6]. The primary outcome was a composite of worsening HF (defined as hospitalization or an urgent visit resulting in inpatient therapy for HF) or cardiovascular death [6]. Over a median follow-up of 18.2 months, the relative reduction in primary outcome in the dapagliflozin group versus the placebo group was 26% (hazard ratio 0.74, 95% CI 0.65-0.85, P< 0.001) [6]. In addition, there was significant improvement in quality of life at 8 months. Importantly, results in patients without diabetes, who constitute 55% of the study population, were similar to those with diabetes [6]. Furthermore, all individual components of the primary outcome were in favor of dapagliflozin (Table 2). The DAPA-HF provides strong evidence that SGLT2 inhibitors do not only decrease incidence of HF but also may serve as actual therapy for HFREF irrespective of presence of diabetes [6].

**Mechanisms of cardiac benefits of SDLT2 inhibitors**

Mechanisms underlying the reduction in HFH of SGLT2 inhibitors are not fully understood and are currently an area of active research. These mechanisms include changes in arterial stiffness and cardiac oxygen demand, and reduction in the following parameters: serum uric acid, tissue sodium, albuminuria, ambulatory blood pressure, and weight [for review see reference 14]. Regarding the relative importance of these mechanisms, several observations have to be considered. First, the fact that reduction in HFH occurred early within the first few months after administration of SGLT2 inhibitors suggests that diuresis and natriuresis by these agents may be early...
mechanisms involved to decrease the after load. Second, it is unlikely that the mild reduction in hemoglobin A1c values (approximately 0.2-0.4% less than placebo) is a significant factor. This notion is supported by the fact that patients without diabetes had similar magnitude of cardiac benefits [6]. Third, recent data do not suggest a positive inotropic action by SGLT2 inhibitors. Thus, using cardiac magnetic resonance imaging, Verma et al [15] showed amelioration of left ventricular mass index after 6 months of empagliflozin therapy, but no significant effect on ejection fraction [15].

**Safety of SGLT2 inhibitors in heart failure**

Overall, SGLT2 inhibitors were well-tolerated as reflected by rates of discontinuation due to adverse effects that are close to placebo [2-4.6]. Likewise, rates of hypoglycemia, acute renal failure are either similar or less than placebo [2-4]. It was particularly reassuring that no major hypoglycemic episodes were reported among patients without diabetes [6]. However, there are 2 adverse effects shared by members of the class. First, genital fungal infections are the commonest adverse effect of SGLT2 inhibitors, particularly in women. Second, diabetic ketoacidosis occurred 2-10 times more frequently with SGLT2 inhibitors than placebo, but the absolute number of events was small. Increased risk of lower limb amputation and fractures previously reported in one large CV trial with canagliflozin [3], were not seen with empagliflozin and dapagliflozin [2,4].

**Rationale [p8] for adding SGLT2 inhibitors to standard therapy of heart failure irrespective of diabetes**

Based on the preceding, SGLT2 inhibitors should be included as part of management of most patients with HFrEF irrespective of presence of diabetes based on the following: first the reduction in HFH is robust and consistent across a wide range of patients’ characteristics [2-4]. Second, the magnitude of decrease in HFH is substantial, was already manifest after few months, and was demonstrated on top of standard treatment of HF [6]. Third, the decrease in HFH by SGLT2 inhibitors was similar in patients with and without diabetes [6]. Fourth, in addition to reduction in HFH and amelioration of symptoms of HF, dapagliflozin significantly reduced CV death and all-cause death [6]. Fifth, SGLT2 inhibitors did not cause major hypoglycemia in patients without diabetes [6].

**Limitation for the recommendation of using SGLT2 inhibitors in all patients with HFrEF**

Despite the encouraging results of dapagliflozin in reducing CV events in patients with HFrEF, patients with NYHA class IV, i.e. patients with more advanced heart failure, were not adequately studied [6]. Thus, less than 1% of patients involved in the DAPA-HF trial pertained to NYHA class IV, whereas approximately 67% and 32% of patients pertained to class II and III, respectively [6][p9].

Therefore, use of SGLT2 inhibitors cannot be recommended in patients with HFrEF class IV until this group of patients is thoroughly evaluated in terms of efficacy and safety.

**Conclusions and Current Directions**

Reduction of HFH by 27-35% is a robust class effect of the 3 SGLT2 inhibitors [2-4]. The relative risk reduction in HFH by these agents emerges few months after starting treatment and is similar in patients with established CV disease and patients with only CV risk factors. In subjects with established HFrEF of NYHA class II and III, dapagliflozin significantly decreased HFH, CV death and all-cause death [6]. Moreover, these benefits extend to patients without diabetes [6]. Based on the available data, the author recommends using SGLT2 inhibitors as a standard therapy for patients HFrEF class II and III, irrespective of presence of diabetes. Randomized trials (n=17 trials) are underway to examine the effects of different SGLT2 inhibitors on clinical and safety outcomes in patients with HF. These trials include patients with and without type 2 diabetes, and with HFrEF as well as HF with preserved Ejection Fraction (HFpEF) i.e. LVEF ≥ 50% [8]. Randomized studies are needed to specifically evaluate efficacy and safety of SGLT2 inhibitors in patients with more advanced HF (i.e. NYHA class IV). The results of these ongoing trials will likely have

### Table 2: Overview and main results of DAPA-HF trial in patients with heart failure and reduced ejection fraction with or without diabetes [6].

| Patients | Randomized, double-blind, multi-center, 2 groups |
|----------|--------------------------------------------------|
| Patients’ disease | Heart failure with ejection fraction ≤40%, NYHA Class II (67%), III (32%), IV (1%). |
| Percentage of patients with/without type 2 diabetes | 45/55 |
| Primary outcome | Composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death |
| Median follow-up | 18.2 months |
| Intervention | Dapagliflozin 10 mg/d (n=2373), placebo (n=2371) |
| Risk reduction in primary outcome with dapagliflozin vs placebo | Dapagliflozin 16.3%, placebo 21.3%, *HR 0.74 (95% CI, 0.65-0.85), P<0.001 |
| Death due to any cause | Dapagliflozin 11.6%, placebo 13.9%, HR 0.83 (95% CI 0.71-0.97) |
| Death due to cardiovascular causes | Dapagliflozin 9.6%, placebo 11.5%, HR 0.82 (95% CI 0.69-0.98) |
| Hospitalization due to heart failure | Dapagliflozin 9.7%, placebo 13.4% HR 0.70 (95% CI 0.59-0.83) |
| Worsening renal function | Dapagliflozin 1.2%, placebo 1.6%, HR 0.71 (95% 0.44-1.16) |
| Percentage of patients with ≥5 increase in the KCCQ ** at 8 months | Dapagliflozin 58.3%, placebo 50.9%, odds ratio, 1.15 (95% CI 1.01-1.23) |
| Discontinuation of study drug due to adverse effects | Dapagliflozin 4.6%, Placebo 4.9% |

*HR: hazard ratio.

** KCCQ: Kansas City Cardiomyopathy Questionnaire. Score is from 0 to 100, with higher score reflects fewer symptoms. An increase in scoring of is considered clinically important ≥5 [6].
great impact on the pending American and International guidelines of HF practice.

References

1. Mikhail N. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. World J Diabetes 2014; 5: 854-859.
2. Zinman B, Wanner C, Fischetti D, Bluhmki E, Hantel S, Matteus M, et al. For the EMP-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117-2128.
3. Neal B, Perkovic V, Mahaffey KW, ZeeuwD, Fulcher G, Erondo N, et al. For the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377: 644-657.
4. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. For the DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347-357.
5. Meer P, Gaggin HK, Dec William. ACC/AHA versus ESC guidelines on heart failure. JACC Comparison. J Am Coll Cardiol. 2019; 73: 2756-2568.
6. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. For the DAPA-HF Trial Committee and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995-2008.
7. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Calvins MM, et al. ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017; 23: 628-651.
8. Seferovic PM, Ponikowski P, Anker SD, Bauschesachs J, Chioncel O, Cleand JGF, et al. Clinical practice update on heart failure: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21: 1169-1186.
9. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich IL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393: 31-39.
10. Yang D, He X, Liang H, Zhang S, Zhong X, Luo C, et al. Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized trials. Cardiovasc Diabetol. 2019; 18: 1-8.
11. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, et al. On behalf of the CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs. The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017; 136: 249-259.
12. Patorno E, Pawar A, Franklin JM, Najafzadeh M, Deruaz-Luet A, Brodovicz KG, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019; 139: 2822-2830.
13. Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucci SE, et al. Dapagliflozin effects on biomarkers, symptoms, and function status in patients with heart failure with reduced ejection fraction. Circulation. 2019; 140: 1463-1476.
14. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZ. Sodium glucose cotransporter-2 inhibition in heart failure. Potential mechanisms, clinical implications, and summary of clinical trials. Circulation. 2017; 136: 1643-1658.
15. Verma S, Mazzer CD, Yan AT, Mason T, Gang V, Hwee T, et al. For the EMPA-HEART Cardio-Link-6 Investigators. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: The EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019; 140: 1693-1702.